As part of World Diabetes Day, the International Diabetes Federation (IDF) released the 6th edition of its Diabetes Atlas, which illustrates the escalating impact of diabetes around the world. The numbers are staggering:
382 million people have diabetes in 2013; by 2035 this will rise to 592 million
The number of people with type 2 diabetes is increasing in every country
80% of people with diabetes live in low- and middle-income countries
The greatest number of people with diabetes are between 40 and 59 years of age
To read more in this year's edition of the Diabetes Atlas, click here
Eli Lilly and Company has announced that we will be investing more than $700 million in order to increase our global insulin manufacturing capacity in Puerto Rico, France and China. The growing diabetes epidemic is a significant and growing global problem, as the numbers released by the IDF released this week demonstrate. Lilly has been manufacturing insulin since it introduced the first commercially available insulin product in 1923. In addition to committing to investments in manufacturing, Lilly will also continue to invest heavily in diabetes research.
And finally: In early November, Professor Meir Perez Pugatch made a presentation at a Montréal InVivo/ Life Sciences Ontario breakfast roundtable on pharma IP protection. His presentation focused on Canada's intellectual property environment and the implications for innovation and growth in the life sciences sector. As Professor Pugatch states in his presentation:
Intellectual property rights are one of the major pillars that support innovation, commercialization and marketing of life-science products and technologies - from the test tube to the market.
While the video is lengthy, if you want to learn everything there is to know about Canada's IP environment, it is worth the watch: